Transform Cancers into Manageable Conditions
Transform Cancers into Manageable Conditions
Load image
Background image
About Us
About Us
Company Overview
We are a global clinical-stage biopharmaceutical company focused on the development of innovative oncology drugs, with our R&D and global clinical operation centers in both China and the United States. We have assembled a world-class management team, built our unique immuno-oncology platforms and partnered with multiple top pharmaceutical companies to promote innovation.
Clinical Pipeline
Clinical Pipeline
R&D Platform
R&D Platform
Global Talent
Global Talent
View More
Background image Background image
Competitive Pipeline
Leveraging collaborations and internal discoveries, we have built a robust pipeline with strong potentials, including 11 drug candidates in development. Currently, four of them are being investigated in clinical trials, which are Buparlisib (AN2025), Pelareorep (AN1004), an oral EP4 antagonist (AN0025) and oral small-molecule PD-L1 inhibitor (AN4005).
View More
Background image Background image
Background image Background image Development Platform Development Platform
Research and Development
Platform
Led by a world-class executive and core R&D team, we have built our unique immuno-oncology platforms. Our innovation team is well positioned to establish ourselves as a leading global presence in the oncology market.
View More
Media
View More